Preeclampsia - Aetiology, current diagnostics and clinical management, new therapy options and future perspectives

Geburtshilfe und Frauenheilkunde

Volumn 72, Issue 12, 2012, Pages 1107-1116

  Tallarek, A C ^a   Huppertz, B ^b   Stepan, H ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

angiogenic balance; hypertensive diseases of pregnancy; preeclampsia

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBRINOLYTIC AGENT; ATENOLOL; BELOC MITE; DIAZEPAM; DIHYDRALAZINE; DIURETIC AGENT; DOPAMINE; FIBRINOGEN CONCENTRATE; FUROSEMIDE; GLUCOCORTICOID; GLUCONATE CALCIUM; HEPARIN; MAGNESIUM SULFATE; METHYLDOPA; METHYLPREDNISOLONE; METOPROLOL TARTRATE; NIFEDIPINE; PHENYTOIN; PLACEBO; PLACENTAL GROWTH FACTOR; PROTHROMBIN; UNCLASSIFIED DRUG; URAPIDIL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ACUTE KIDNEY FAILURE; ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; BLEEDING; CONSERVATIVE TREATMENT; DISSEMINATED INTRAVASCULAR CLOTTING; DOPPLER ECHOGRAPHY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; EARLY DIAGNOSIS; ENDOTHELIUM CELL; ERYTHROCYTE CONCENTRATE; FETUS DEVELOPMENT; FETUS MONITORING; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEADACHE; HELLP SYNDROME; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; LUNG EDEMA; MATERNAL HYPERTENSION; PATHOGENESIS; PREECLAMPSIA; PREGNANCY TERMINATION; PROGNOSIS; PROTEINURIA; RESPIRATION DEPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; TACHYCARDIA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TROPHOBLAST;

EID: 84871191383     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0032-1328080     Document Type: Review

References (39)

1. Bolte A. C., van Geijn H. P., Dekker G. A. Management and monitoring of severe preeclampsia. Eur J Obstet Gynecol Reprod Biol: 2001; 96 8 20
2. Goldenberg R. L., Culhane J. F., Iams J. D. et al. Epidemiology and causes of preterm birth. Lancet: 2008; 371 75 84
3. Smith G. C., Pell J. P., Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet: 2001; 357 2002 2006
4. Garovic V. D., Hayman S. R. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol: 2007; 3 613 622
5. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension: 2008; 51 970 975
6. Huppertz B. Placental pathology in pregnancy complications. Thromb Res: 2011; 127 03 S96 S99
7. Roberts J. M., Taylor R. N., Musci T. J. et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol: 1989; 161 1200 1204
8. Levine R. J., Maynard S. E., Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med: 2004; 350 672 683
9. Staff A. C., Braekke K., Harsem N. K. et al. Circulating concentrations of sFlt1/Soluble fms-like tyrosine kinase 1 in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol: 2005; 122 33 39
10. Chaiworapongsa T., Romero R., Kim Y. M. et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med: 2005; 17 3 18
11. Hladunewich M., Ananth Karumanchi S., Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol: 2007; 2 543 549
12. Osmanagaoglu M. A., Karahan S. C., Aran T. et al. Predictive value of plasma total carnitine, arginine, asymmetric dimethylarginine and ischemia-modified albumin levels and their combined use in the early detection of preeclampsia. Geburtsh Frauenheilk: 2011; 71 773 778
13. Milne F., Redman C., Walker J. et al. PRECOG II Group Assessing the onset of pre-eclampsia in the hospital day unit: summary of the pre-eclampsia guideline (PRECOG II). BMJ: 2009; 339 b3129
14. Stepan H., Schaarschmidt W., Jank A. et al. Angiogene Faktoren zur Diagnosesicherung bei Präeklampsie in der klinischen Routine: erste Erfahrungen. Z Geb Neonatol: 2010; 214 234 238
15. Verlohren S., Herraiz I., Lapaire O. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol: 2012; 206 58.e1 58.e8
16. Rana S., Hacker M. R., Modest A. M. et al. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension: 2012; 60 451 458
17. Poon L. C., Maiz N., Valencia C. et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol: 2009; 33 23 33
18. Lapaire O., Shennan A., Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol: 2010; 151 122 129
19. Akolekar R., Syngelaki A., Sarquis R. et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn: 2011; 31 66 74
20. Rath W., Fischer T., Klockenbusch W. Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. Leitlinie der Arbeitsgemeinschaft Schwangerschaftshochdruck/Gestose der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e.V. (DGGG), AWMF-Leitlinien-Register Nr. 015/018, letzte Aktualisierung 05/2008.
21. Panchal S., Arria A. M., Harris A. P. Intensive care utilization during hospital admission for delivery: prevalence, risk factors, and outcomes in a statewide population. Anesthesiology: 2000; 92 1537 1544
22. Abalos E., Duley L., Steyn D. W. et al. Antihypertensive drug therapy for mild to moderate hypertension in pregnancy. Cochrane Database Syst Rev: 2007; 1 CD002252
23. Ferrer R. L., Sibai B. M., Multrow C. D. et al. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol: 2000; 96 849 860
24. Helewa M. E., Burrows R. F., Smith J. et al. Report of the Canadian Hypertension Society consensus conference: 1. Definitions, evaluations and classification of hypertensive disorders in pregnancy. CMAJ: 1997; 157 715
25. Lucas M. J., Leveno K. J., Cunnningham F. G. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med: 1995; 333 201
26. Schott M., Henkelmann A., Meinkoehn Y. et al. Postpartale Eklampsie und fulminantes HELLP-Syndrom. Anaesthesist: 2011; 60 343 351
27. Woudstra D. M., Chandra S., Hofmeyr G. J. et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev: 2010; 9 CD008148
28. Sibai B. M. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes and low platelet count. Obstet Gynecol: 2004; 103 981
29. Klockenbusch W., Fischer T. Präeklampsie. Kapitel 8: Medikamentöse Therapie. Bremen Uni-Med: 2005; 76 80
30. Duley L., Henderson-Smart D. J., Meher S. et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev: 2007; 2 CD004659
31. Bujold E., Roberge S., Lacasse Y. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol: 2010; 116 2 Pt 1 402 414
32. Rey E., Garneau P., David M. et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost: 2009; 45 86
33. Kupferminc M. J., Rimon E., Many A. et al. Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern Fetal Neonatal Med: 2011; 24 1042 1045
34. Martinelli I., Ruggenenti P., Cetin I. et al. HAPPY Study Group Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood: 2012; 119 3269 3275
35. Thadhani R., Kisner T., Hagmann H. et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation: 2011; 124 940 950
36. McCarthy F. P., Drewlo S., English F. A. et al. Evidence implicating peroxisome proliferator-activated receptor-γ in the pathogenesis of preeclampsia. Hypertension: 2011; 58 882 887
37. McCarthy F. P., Drewlo S., Kingdom J. et al. Peroxisome proliferator-activated receptor-γ as a potential therapeutic target in the treatment of preeclampsia. Hypertension: 2011; 58 280 286
38. 2 as possible risk factors for preeclampsia - under consideration of the PROPER study ("Prevention of preeclampsia by high-dose riboflavin supplementationo"). Geburtsh Frauenheilk: 2012; 72 846 852
39. Walker J. J. Pre-eclampsia. Lancet: 2000; 356 1260 1265